Table 3. Comparison of EGFR mutated tumors with EGFR wildtype, pan-negative and ALK positive tumors.
| Variable |
EGFR mt (n = 81) |
EGFR wt (n = 57) |
p | Pan-negative (n = 13) |
p |
ALK positive (n = 17) |
p |
|---|---|---|---|---|---|---|---|
| Age (years) | 61.9 ± 13.4 | 65.3 ± 12.6 | 0.133 | 71.9 ± 9.2 | 0.011 | 64.2 ± 14.0 | 0.515 |
| Gender | 0.225 | 0.250 | 0.097 | ||||
| Male | 30 (37.0) | 27 (47.4) | 7 (53.8) | 10 (58.8) | |||
| Female | 51 (63.0) | 30 (52.6) | 6 (46.2) | 7 (41.2) | |||
| Clinical stage | |||||||
| I | 6 (7.4) | 3 (5.3) | 0.736 | 1 (7.7) | 0.971 | 0 (0.0) | 0.586 |
| II | 5 (6.2) | 6 (10.5) | 0.361 | 1 (7.7) | 0.839 | 2 (11.8) | 0.601 |
| III | 10 (12.3) | 13 (22.8) | 0.104 | 3 (23.1) | 0.381 | 5 (29.4) | 0.130 |
| IV | 60 (74.1) | 35 (61.4) | 0.114 | 8 (61.5) | 0.339 | 10 (58.8) | 0.242 |
| T stage | |||||||
| T1 | 11 (13.6) | 8 (14.0) | 0.939 | 0 (0.0) | 0.352 | 3 (17.6) | 0.705 |
| T2 | 25 (30.9) | 14 (24.6) | 0.418 | 4 (30.8) | 0.995 | 4 (23.5) | 0.547 |
| T3 | 18 (22.2) | 7 (12.3) | 0.135 | 1 (7.7) | 0.455 | 2 (11.8) | 0.670 |
| T4 | 27 (33.3) | 28 (49.1) | 0.062 | 8 (61.5) | 0.066 | 2 (11.8) | 0.537 |
| LN meta | 59 (72.8) | 46 (80.7) | 0.286 | 10 (76.9) | 0.754 | 15 (88.2) | 0.228 |
| N stage | |||||||
| N0 | 22 (27.2) | 11 (19.3) | 0.286 | 3 (23.1) | 0.754 | 2 (11.8) | 0.228 |
| N1 | 10 (12.3) | 6 (10.5) | 0.742 | 2 (15.4) | 0.670 | 1 (5.9) | 0.683 |
| N2 | 18 (22.2) | 21 (36.8) | 0.060 | 3 (23.1) | 0.945 | 9 (52.9) | 0.016 |
| N3 | 31 (38.3) | 19 (33.3) | 0.552 | 5 (38.5) | 0.990 | 5 (29.4) | 0.491 |
| Extrathoracic meta | 45 (55.6) | 20 (35.1) | 0.018 | 5 (38.5) | 0.252 | 5 (29.4) | 0.050 |
| M stage | |||||||
| M0 | 21 (25.9) | 22 (38.6) | 0.114 | 5 (38.5) | 0.339 | 7 (41.2) | 0.242 |
| M1a | 15 (18.5) | 15 (26.3) | 0.274 | 5 (38.5) | 0.709 | 5 (29.4) | 0.330 |
| M1b | 12 (14.8) | 6 (10.5) | 0.461 | 1 (7.7) | 0.686 | 0 (0.0) | 0.119 |
| M1c | 33 (40.7) | 14 (24.6) | 0.048 | 4 (30.8) | 0.495 | 5 (29.4) | 0.383 |
| Localization | |||||||
| Right upper lobe | 23 (28.4) | 8 (14.0) | 0.047 | 0 (0.0) | 0.033 | 0 (0.0) | 0.010 |
| Right lower lobe | 6 (7.4) | 8 (14.0) | 0.204 | 3 (23.1) | 0.107 | 2 (11.8) | 0.624 |
| Middle lobe | 5 (6.2) | 3 (5.3) | 0.821 | 1 (7.7) | 0.839 | 2 (11.8) | 0.601 |
| Left upper lobe | 15 (18.5) | 12 (21.1) | 0.712 | 3 (23.1) | 0.709 | 4 (23.5) | 0.736 |
| Left lower lobe | 12 (14.8) | 10 (17.5) | 0.666 | 2 (15.4) | 0.957 | 3 (17.6) | 0.721 |
| Lingula | 0 (0.0) | 2 (3.5) | 0.169 | 0 (0.0) | - | 1 (5.9) | 0.173 |
| Mixed | 20 (24.7) | 14 (24.6) | 0.986 | 4 (30.8) | 0.733 | 5 (29.4) | 0.761 |
| Distribution | |||||||
| Central | 18 (22,2) | 14 (24.6) | 0.749 | 3 (23.1) | 0.945 | 6 (35.3) | 0.351 |
| Peripheral | 50 (61.7) | 33 (57.9) | 0.651 | 6 (46.2) | 0.288 | 7 (41.2) | 0.118 |
| Central and peripheral | 13 (16.0) | 10 (17.5) | 0.817 | 4 (30.8) | 0.243 | 4 (23.5) | 0.487 |
| Malignant PE | 28 (34.6 | 12 (21.1) | 0.085 | 4 (30.8) | 0.787 | 4 (23.5) | 0.378 |
| Size (mm) | 45.7 ± 21.9 | 47.1 ± 28.0 | 0.755 | 55.0 ± 28.9 | 0.180 | 50.4 ± 36.9 | 0.486 |
| Brain meta at diagnosis | 15 (18.5) | 6 (10.5) | 0.198 | 2 (15.4) | 0.782 | 2 (11.8) | 0.729 |
| Brain meta at diagnosis and during follow-up |
23 (28.4) | 15 (26.3) | 0.788 | 4 (30.8) | 0.861 | 6 (35.3) | 0.571 |
Data are mean values ± standard deviations for continuous variables and number of patients with percentages in parentheses for categorical variables.
Bold numbers indicate significant p-values (< 0.05).